- Home
- NDMO vs LAB Comparison
NDMO vs LAB Comparison
Compare NDMO & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NDMO | LAB |
|---|---|---|
| Founded | 2019 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 622.4M | 449.9M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | NDMO | LAB |
|---|---|---|
| Price | $10.04 | $1.67 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $1.35 |
| AVG Volume (30 Days) | 218.6K | ★ 2.0M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 6.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $169,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 79.77 |
| 52 Week Low | $8.99 | $0.92 |
| 52 Week High | $11.24 | $2.25 |
Technical Indicators
Market Signals| Indicator | NDMO | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 30.38 | 74.87 |
| Support Level | $10.00 | $1.46 |
| Resistance Level | $10.22 | $1.51 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 6.06 | 98.21 |
Price Performance
Historical ComparisonAbout NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.